financetom
Business
financetom
/
Business
/
ENDRA Life Sciences Gains Momentum With Crypto-Focused Treasury Plan
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ENDRA Life Sciences Gains Momentum With Crypto-Focused Treasury Plan
Oct 13, 2025 9:41 AM

ENDRA Life Sciences Inc. ( NDRA ) shares jumped after the company announced $4.9 million in funding commitments from institutional and cryptocurrency investors to launch a new digital asset treasury strategy.

The initiative will focus on high-conviction decentralized finance holdings managed by Arca Investment Management LLC. The private placement includes 744,340 shares of common stock, as well as prefunded warrants and additional warrants to purchase up to 1,488,680 shares.

The securities were priced at $6.57 per unit, with warrants exercisable at $6.32 per share for five years. The deal is expected to close around Oct. 14, 2025, pending customary conditions.

Also Read: Aethlon Medical Shares Soar After New Securities Offering Filing

If fully exercised, the warrants could bring total proceeds to $14.4 million. The company stated that most of the funds will support its digital asset treasury operations and cryptocurrency accumulation, while a portion will be allocated to its TAEUS imaging study, which targets metabolic-associated liver diseases.

ENDRA also plans to appoint Jeff Dorman, Chief Investment Officer of Arca, to its Digital Asset Advisory Board. Dorman, who previously worked at Merrill Lynch and Citadel, brings over 25 years of investment management experience and will help guide ENDRA’s crypto treasury strategy.

“Establishing a digital asset treasury is a logical extension of our capital allocation strategy,” said Alexander Tokman, CEO of ENDRA. He stated that the company aims to combine long-term digital asset exposure with DeFi-native yield strategies to create sustainable value and manage risk effectively.

Price Action: NDRA shares were trading higher by 26.85% to $8.22 at last check Monday.

Read Next:

Gilead Sciences/Arcus Biosciences’ Investigational Cancer Drug Shows Overall Survival Of Around 27 Months

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vital Energy Insider Sold Shares Worth $5,469,188, According to a Recent SEC Filing
Vital Energy Insider Sold Shares Worth $5,469,188, According to a Recent SEC Filing
Jul 11, 2025
04:46 PM EDT, 07/11/2025 (MT Newswires) -- Richard D Campbell, 10% Owner, on July 09, 2025, sold 300,000 shares in Vital Energy ( VTLE ) for $5,469,188. Following the Form 4 filing with the SEC, Campbell has control over a total of 7,568,933 common shares of the company, with 7,568,933 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1528129/000177446325000004/xslF345X05/primary_doc.xml ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Salesforce Insider Sold Shares Worth $598,854, According to a Recent SEC Filing
Salesforce Insider Sold Shares Worth $598,854, According to a Recent SEC Filing
Jul 11, 2025
04:48 PM EDT, 07/11/2025 (MT Newswires) -- Marc Benioff, Director, Chair and CEO, on July 10, 2025, sold 2,250 shares in Salesforce ( CRM ) for $598,854. Following the Form 4 filing with the SEC, Benioff has control over a total of 22,062,566 common shares of the company, with 11,955,566 shares held directly and 10,107,000 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1108524/000112760225019093/xslF345X05/form4.xml...
US FDA declines to approve Ultragenyx's gene therapy for rare inherited disorder
US FDA declines to approve Ultragenyx's gene therapy for rare inherited disorder
Jul 11, 2025
July 11 (Reuters) - The U.S. Food and Drug Administration has declined to approve Ultragenyx Pharmaceutical's ( RARE ) experimental gene therapy to treat a rare inherited disorder, citing manufacturing concerns, the company said on Friday. The therapy, UX111, was developed to treat Sanfilippo syndrome type A - a rare, inherited disorder that begin in early childhood causing severe brain...
Copyright 2023-2026 - www.financetom.com All Rights Reserved